DK1334119T4 - Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet - Google Patents
Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet Download PDFInfo
- Publication number
- DK1334119T4 DK1334119T4 DK01987765.3T DK01987765T DK1334119T4 DK 1334119 T4 DK1334119 T4 DK 1334119T4 DK 01987765 T DK01987765 T DK 01987765T DK 1334119 T4 DK1334119 T4 DK 1334119T4
- Authority
- DK
- Denmark
- Prior art keywords
- glycoprotein
- respiratory syncytial
- rsv
- syncytial virus
- cx3c
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000036039 immunity Effects 0.000 title abstract description 15
- 230000027455 binding Effects 0.000 claims abstract description 117
- 108010015329 Respiratory syncytial virus G glycoprotein Proteins 0.000 claims abstract description 70
- 241000700605 Viruses Species 0.000 claims abstract description 41
- 230000000903 blocking effect Effects 0.000 claims abstract description 37
- 201000010099 disease Diseases 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 21
- 230000004071 biological effect Effects 0.000 claims abstract description 19
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 108090000288 Glycoproteins Proteins 0.000 claims description 234
- 102000003886 Glycoproteins Human genes 0.000 claims description 234
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 201
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 197
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims description 96
- 102000004298 CX3C Chemokine Receptor 1 Human genes 0.000 claims description 89
- 230000005764 inhibitory process Effects 0.000 claims description 38
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 102000005962 receptors Human genes 0.000 claims description 26
- 108020003175 receptors Proteins 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 17
- 235000018417 cysteine Nutrition 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000035605 chemotaxis Effects 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 8
- 230000012292 cell migration Effects 0.000 claims description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 abstract description 70
- 208000015181 infectious disease Diseases 0.000 abstract description 33
- 102000019034 Chemokines Human genes 0.000 abstract description 27
- 108010012236 Chemokines Proteins 0.000 abstract description 27
- 230000006698 induction Effects 0.000 abstract description 5
- 230000002452 interceptive effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 144
- 102000004196 processed proteins & peptides Human genes 0.000 description 134
- 101150030419 Cx3cl1 gene Proteins 0.000 description 75
- 229920001184 polypeptide Polymers 0.000 description 67
- 150000007523 nucleic acids Chemical class 0.000 description 56
- 108020004707 nucleic acids Proteins 0.000 description 53
- 102000039446 nucleic acids Human genes 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 48
- 102000004169 proteins and genes Human genes 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 37
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 32
- 229920000669 heparin Polymers 0.000 description 31
- 229960002897 heparin Drugs 0.000 description 31
- 230000003399 chemotactic effect Effects 0.000 description 23
- 241000283973 Oryctolagus cuniculus Species 0.000 description 20
- 210000003501 vero cell Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 210000000265 leukocyte Anatomy 0.000 description 18
- 238000010186 staining Methods 0.000 description 16
- 239000013598 vector Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 238000011725 BALB/c mouse Methods 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000011268 leukocyte chemotaxis Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 206010006448 Bronchiolitis Diseases 0.000 description 10
- 102000013818 Fractalkine Human genes 0.000 description 10
- 241000711920 Human orthopneumovirus Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 230000007501 viral attachment Effects 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000005012 migration Effects 0.000 description 9
- 238000013508 migration Methods 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 230000000241 respiratory effect Effects 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000008827 biological function Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 210000002345 respiratory system Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 229920002683 Glycosaminoglycan Polymers 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 206010057190 Respiratory tract infections Diseases 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 6
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 108010054155 lysyllysine Proteins 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- UWQJHXKARZWDIJ-ZLUOBGJFSA-N Ala-Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O UWQJHXKARZWDIJ-ZLUOBGJFSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108091006027 G proteins Proteins 0.000 description 5
- 102000030782 GTP binding Human genes 0.000 description 5
- 108091000058 GTP-Binding Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 150000001945 cysteines Chemical class 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 102000012000 CXCR4 Receptors Human genes 0.000 description 4
- 108010061299 CXCR4 Receptors Proteins 0.000 description 4
- 108050000299 Chemokine receptor Proteins 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 4
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- MTHRMUXESFIAMS-DCAQKATOSA-N Pro-Asn-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O MTHRMUXESFIAMS-DCAQKATOSA-N 0.000 description 4
- 229940124679 RSV vaccine Drugs 0.000 description 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- -1 but not limited to Chemical class 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000002975 chemoattractant Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000007505 plaque formation Effects 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 102000001902 CC Chemokines Human genes 0.000 description 3
- 108010040471 CC Chemokines Proteins 0.000 description 3
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000019388 CXC chemokine Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010014950 Eosinophilia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 229940044627 gamma-interferon Drugs 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 208000030500 lower respiratory tract disease Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 229940031462 non-live vaccine Drugs 0.000 description 3
- 229940023146 nucleic acid vaccine Drugs 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- ZYPWIUFLYMQZBS-SRVKXCTJSA-N Asn-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZYPWIUFLYMQZBS-SRVKXCTJSA-N 0.000 description 2
- 241000711895 Bovine orthopneumovirus Species 0.000 description 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
- 108091008927 CC chemokine receptors Proteins 0.000 description 2
- 102000005674 CCR Receptors Human genes 0.000 description 2
- 102000002214 CXC chemokine receptor 2 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- XHBYEMIUENPZLY-GMOBBJLQSA-N Ile-Pro-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O XHBYEMIUENPZLY-GMOBBJLQSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710128560 Initiator protein NS1 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 2
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 101000746021 Mus musculus CX3C chemokine receptor 1 Proteins 0.000 description 2
- 241000700562 Myxoma virus Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 101710144127 Non-structural protein 1 Proteins 0.000 description 2
- 101710144128 Non-structural protein 2 Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 101710199667 Nuclear export protein Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- VLIUBAATANYCOY-GBALPHGKSA-N Thr-Cys-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O VLIUBAATANYCOY-GBALPHGKSA-N 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 101150044134 US28 gene Proteins 0.000 description 2
- HPOSMQWRPMRMFO-GUBZILKMSA-N Val-Pro-Cys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N HPOSMQWRPMRMFO-GUBZILKMSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000022023 interleukin-5 production Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013391 scatchard analysis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HRANPRDGABOKNQ-ORGXEYTDSA-N (1r,3r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-3-hydroxy-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 HRANPRDGABOKNQ-ORGXEYTDSA-N 0.000 description 1
- SWQQELWGJDXCFT-PNHWDRBUSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide Chemical compound C#CC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWQQELWGJDXCFT-PNHWDRBUSA-N 0.000 description 1
- QZKOOEFIMWKZPK-UHFFFAOYSA-N 2-[(6-carbamimidoyl-1h-benzimidazol-2-yl)methyl]-3h-benzimidazole-5-carboximidamide Chemical compound C1=C(C(N)=N)C=C2NC(CC3=NC4=CC=C(C=C4N3)C(=N)N)=NC2=C1 QZKOOEFIMWKZPK-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- GNYUVVJYGJFKHN-RVMXOQNASA-N Arg-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N GNYUVVJYGJFKHN-RVMXOQNASA-N 0.000 description 1
- IDUUACUJKUXKKD-VEVYYDQMSA-N Asn-Pro-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O IDUUACUJKUXKKD-VEVYYDQMSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 108050005711 C Chemokine Proteins 0.000 description 1
- 102000017483 C chemokine Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102000004325 CX3C Chemokines Human genes 0.000 description 1
- 108010081635 CX3C Chemokines Proteins 0.000 description 1
- 102000011815 CX3C chemokine domains Human genes 0.000 description 1
- 108050002276 CX3C chemokine domains Proteins 0.000 description 1
- 101150062345 CX3CR1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- MKMKILWCRQLDFJ-DCAQKATOSA-N Cys-Lys-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MKMKILWCRQLDFJ-DCAQKATOSA-N 0.000 description 1
- KVCJEMHFLGVINV-ZLUOBGJFSA-N Cys-Ser-Asn Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KVCJEMHFLGVINV-ZLUOBGJFSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100035428 Formiminotransferase N-terminal subdomain-containing protein Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000877728 Homo sapiens Formiminotransferase N-terminal subdomain-containing protein Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000725296 JDV virus Species 0.000 description 1
- 241000007938 Juquitiba virus Species 0.000 description 1
- 101150045458 KEX2 gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100373201 Mus musculus Cx3cl1 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100264172 Oryza sativa subsp. japonica XIAO gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- JQOHKCDMINQZRV-WDSKDSINSA-N Pro-Asn Chemical compound NC(=O)C[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 JQOHKCDMINQZRV-WDSKDSINSA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- MDAWMJUZHBQTBO-XGEHTFHBSA-N Pro-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1)O MDAWMJUZHBQTBO-XGEHTFHBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- DLPXTCTVNDTYGJ-JBDRJPRFSA-N Ser-Ile-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O DLPXTCTVNDTYGJ-JBDRJPRFSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QWMPARMKIDVBLV-VZFHVOOUSA-N Thr-Cys-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O QWMPARMKIDVBLV-VZFHVOOUSA-N 0.000 description 1
- ODSAPYVQSLDRSR-LKXGYXEUSA-N Thr-Cys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O ODSAPYVQSLDRSR-LKXGYXEUSA-N 0.000 description 1
- KZUJCMPVNXOBAF-LKXGYXEUSA-N Thr-Cys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KZUJCMPVNXOBAF-LKXGYXEUSA-N 0.000 description 1
- UCCNDUPVIFOOQX-CUJWVEQBSA-N Thr-Cys-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 UCCNDUPVIFOOQX-CUJWVEQBSA-N 0.000 description 1
- NRBUKAHTWRCUEQ-XGEHTFHBSA-N Thr-Cys-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(O)=O NRBUKAHTWRCUEQ-XGEHTFHBSA-N 0.000 description 1
- WFAUDCSNCWJJAA-KXNHARMFSA-N Thr-Lys-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(O)=O WFAUDCSNCWJJAA-KXNHARMFSA-N 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical class [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003725 proteoliposome Substances 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- HOZOZZFCZRXYEK-HNHWXVNLSA-M scopolamine butylbromide Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-HNHWXVNLSA-M 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CSRCBLMBBOJYEX-UHFFFAOYSA-M sodium;2-morpholin-4-ylethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OS(=O)(=O)CCN1CCOCC1 CSRCBLMBBOJYEX-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (28)
1. Sammensætning, der omfatter et blokerende molekyle, som inhiberer den biologiske aktivitet af et CX3C-sekvenstema i et respiratorisk syncytialvirus G-glycoprotein, hvori C er en cysteinrest, og X er en hvilken som helst aminosy-rerest ud over cystein, hvor det blokerende molekyle er et peptid bestående af en sekvens, der er valgt blandt SEQ ID NO. 3, 5, 6, 7, 8, 9, 10 eller 11, til inhibering af binding af respiratorisk syncytialvirus G-glycoproteinet til en CX3CR1 -receptor.
2. Sammensætning ifølge krav 1, hvori det blokerende molekyle binder til CX3C-receptoren.
3. Sammensætning ifølge krav 1, hvori det blokerende molekyle er et peptid bestående af sekvensen TCAAACKRIPNKK (SEQ ID NO:5).
4. Sammensætning ifølge krav 1, hvori det blokerende molekyle er et peptid bestående af sekvensen TCWAACKRIPNKK (SEQ ID NO:6).
5. Sammensætning ifølge krav 1, hvori det blokerende molekyle er et peptid bestående af sekvensen TCNAACKRIPNKK (SEQ ID NO:7).
6. Sammensætning ifølge krav 1, hvori det blokerende molekyle er et peptid bestående af sekvensen TCDAACKRIPNKK (SEQ ID NO:8).
7. Sammensætning ifølge krav 1, hvori det blokerende molekyle er et peptid bestående af sekvensen TCHAACKRIPNKK (SEQ ID NO:9).
8. Sammensætning ifølge krav 1, hvori det blokerende molekyle er et peptid bestående af sekvensen TCMAACKRIPNKK (SEQ ID NO:10).
9. Sammensætning ifølge krav 1, hvori det blokerende molekyle er et peptid bestående af sekvensen TCFAACKRIPNKK (SEQ ID NO:11).
10. Sammensætning ifølge krav 1, hvori det blokerende molekyle er et peptid bestående af sekvensen TCWAICKRIPNK (SEQ ID NO:3).
11. Sammensætning ifølge krav 1, hvori den biologiske aktivitet er kemotaksis, cellevandring eller virus-adhæsion til celler.
12. Respiratorisk syncytialvirus, der omfatter et CX3C-sekvenstema i respiratorisk syncytialvirus G-glycoprotein, som er ikke-funktionelt til fastgørelse af virusset til en CX3C-R1-receptor på en celle, hvori C er en cysteinrest, og X er en hvilken som helst aminosyre ud over cystein.
13. Respiratorisk syncytialvirus ifølge krav 12, hvor virusset er et levende virus.
14. Respiratorisk syncytialvirus ifølge krav 12, hvor virusset er et ikke-levende virus.
15. Sammensætning, der omfatter et peptid ifølge krav 1, til anvendelse til induktion afen immunreaktion i en person.
16. In v/Yro-fremgangsmåde til identificering af et stof, der er egnet til behandling eller forebyggelse af respiratorisk syncytialvirussygdom, som omfatter kontaktbringning af stoffet med en CX3C-receptor i nærvær af respiratorisk syncytialvirus G-glycoprotein og påvisning af inhibering af glycoproteinbinding til CX3C-receptoren, hvorved påvisning af inhibering af respiratorisk syncytialvirus G-glycoproteinbinding til CX3C-receptoren identificerer et stof, der er egnet til behandling eller forebyggelse af respiratorisk syncytialvirussygdom.
17. Fremgangsmåde ifølge krav 16, hvorved stoffet binder til CX3C-sekvens-temaet i respiratorisk syncytialvirus G-glycoproteinet.
18. Fremgangsmåde ifølge krav 16, hvorved stoffet binder til CX3C-recepto-ren.
19. In v/Yro-fremgangsmåde til identificering af et stof til behandling eller forebyggelse af respiratorisk syncytialvirussygdom, som omfatter kontaktbringning af stoffet med en CX3C-receptor-indeholdende celle i nærvær af respiratorisk syncytialvirus og påvisning af inhibering af en biologisk aktivitet, der er forbundet med respiratorisk syncytialvirusbinding til CX3C-receptoren, hvorved påvisning af inhibering afen biologisk aktivitet, der er forbundet med respiratorisk syncytialvirusbinding til CX3C-receptoren, identificerer et stof, der er egnet til behandling eller forebyggelse af respiratorisk syncytialvirussygdom.
20. Sammensætning, der omfatter et peptid ifølge krav 1, til anvendelse til behandling af respiratorisk syncytialvirusinfektion hos en person, der er inficeret med respiratorisk syncytialvirus.
21. Sammensætning, der omfatter et blokerende molekyle, som inhibererden biologiske aktivitet af et CX3C-sekvenstema i et respiratorisk syncytialvirus G-glycoprotein, hvori C er en cysteinrest, og X er en hvilken som helst aminosy-rerest ud over cystein, hvor det blokerende molekyle er et antistof, der er dannet mod et peptid bestående af en sekvens, der er valgt blandt SEQ ID NO:3, 5, 6, 7, 8, 9, 10 eller 11, til inhibering af binding af respiratorisk syncytialvirus G-glycoproteinet til en CX3CR1-receptor, hvorved antistoffet binder specifikt til aminosyrepositionerne 182-186 i et naturligt forekommende respiratorisk syncytialvirus G-glycoprotein eller blokerer aktiviteten, der er forbundet med binding til CX3CR1-receptoren, og hvor antistoffet binder til peptidet bestående af sekvensen TCWAICKRIPNK (SEQ ID NO:3), til anvendelse til behandling af respiratorisk syncytialvirusinfektion hos en person, der er inficeret med respiratorisk syncytialvirus.
22. Anvendelse af respiratorisk syncytialvirus ifølge krav 12 til fremstilling af en sammensætning til forebyggelse af respiratorisk syncytialvirusinfektion hos en person.
23. Anvendelse af sammensætningen ifølge krav 1 til fremstilling af en formulering til induktion afen immunreaktion i en person, hvor formuleringen omfatter en immunogen mængde af sammensætningen ifølge krav 1 og en farmaceutisk acceptabel bærer.
24. Anvendelse af en sammensætning, der omfatter et blokerende molekyle, som inhiberer den biologiske aktivitet af et CX3C-sekvenstema i et respiratorisk syncytialvirus G-glycoprotein, hvori C er en cysteinrest, og X er en hvilken som helst aminosyrerest ud over cystein, hvor det blokerende molekyle er et antistof, der er dannet mod et peptid bestående af en sekvens, der er valgt blandt SEQ ID NO:3, 5, 6, 7, 8, 9, 10 eller 11 til inhibering af binding af respiratorisk syncytialvirus G-glycoproteinet til en CX3CR1-receptor, hvorved antistoffet binder specifikt til aminosyrepositionerne 182-186 i et naturligt forekommende respiratorisk syncytialvirus G-glycoprotein eller blokerer aktiviteten, der er forbundet med binding til CX3CR1-receptoren, og hvor antistoffet binder til peptidet bestående af sekvensen TCWAICKRIPNK (SEQ ID NO:3) til fremstilling af en formulering til induktion af en immunreaktion i en person, hvor formuleringen omfatter en immunogen mængde af antistoffet og en farmaceutisk acceptabel bærer.
25. Anvendelse af et virus ifølge krav 12 til fremstilling afen formulering til induktion af en immunreaktion i en person, hvor formuleringen omfatter en immunogen mængde af virusset ifølge krav 12 og en farmaceutisk acceptabel bærer.
26. Respiratorisk syncytialvirus ifølge krav 12, hvor virusset omfatter en deletionsmutation i aminosyresekvensen for CX3C-sekvenstemaet.
27. Respiratorisk syncytialvirus ifølge krav 12, hvori aminosyresekvensen for CX3C-sekvenstemaet er deleteret.
28. Respiratorisk syncytialvirus ifølge krav 12, hvor virusset omfatter en inser-tionsmutation i aminosyresekvensen for CX3C-sekvenstemaet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24152100P | 2000-10-18 | 2000-10-18 | |
| PCT/US2001/032459 WO2002032942A2 (en) | 2000-10-18 | 2001-10-18 | Compositions and methods for modulating rsv infection and immunity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK1334119T3 DK1334119T3 (da) | 2009-02-23 |
| DK1334119T4 true DK1334119T4 (da) | 2019-03-18 |
Family
ID=22911027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01987765.3T DK1334119T4 (da) | 2000-10-18 | 2001-10-18 | Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20040009177A1 (da) |
| EP (1) | EP1334119B2 (da) |
| AT (1) | ATE412666T1 (da) |
| AU (2) | AU2002224416A1 (da) |
| CA (1) | CA2426312C (da) |
| DE (1) | DE60136381D1 (da) |
| DK (1) | DK1334119T4 (da) |
| ES (1) | ES2316487T5 (da) |
| WO (1) | WO2002032942A2 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1768993A4 (en) * | 2004-06-16 | 2008-07-23 | Univ Johns Hopkins | CYSTIC REGION OF HUMAN RESPIRATORY SYNZYTIAL VIRUS AND METHOD OF USE THEREOF |
| KR20080113223A (ko) * | 2006-03-06 | 2008-12-29 | 심포젠 에이/에스 | 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체 |
| WO2008106980A2 (en) * | 2007-03-06 | 2008-09-12 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
| JP5808536B2 (ja) * | 2007-10-25 | 2015-11-10 | トレリス バイオサイエンス、インク． | 抗ｒｓｖｇタンパク質抗体 |
| GB0724253D0 (en) * | 2007-12-12 | 2008-01-30 | Fermentas Uab | Transfection reagent |
| SG190562A1 (en) * | 2008-04-18 | 2013-06-28 | Vaxinnate Corp | Deletion mutants of flagellin and methods of use |
| WO2010075491A2 (en) * | 2008-12-24 | 2010-07-01 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
| US8846056B2 (en) | 2009-08-04 | 2014-09-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control | Anti-RSV immunogens and methods of immunization |
| US9856456B2 (en) | 2009-10-12 | 2018-01-02 | Thermo Fisher Scientific Baltics Uab | Delivery agent |
| GB0917792D0 (en) | 2009-10-12 | 2009-11-25 | Fermentas Uab | Delivery agent |
| AU2011276251B2 (en) | 2010-07-07 | 2015-02-05 | Artifical Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
| KR101489129B1 (ko) * | 2010-07-28 | 2015-02-04 | 닛산 지도우샤 가부시키가이샤 | 쌍극형 전극 및 그것을 사용한 쌍극형 2차 전지와 쌍극형 전극의 제조 방법 |
| IN2015DN01448A (da) | 2012-08-01 | 2015-07-03 | Bavarian Nordic As | |
| EP2993009A1 (de) * | 2014-09-08 | 2016-03-09 | HILTI Aktiengesellschaft | Verfahren zur Steuerung eines Wandsägesystems beim Erstellen eines Trennschnittes |
| SE539731C2 (sv) | 2016-03-04 | 2017-11-14 | Vertical Wind Ab | Rotor för en elektrisk generator och förfarande för dess tillverkning |
| US11773143B2 (en) | 2017-10-13 | 2023-10-03 | Trellis Bioscience, Llc | Conformational epitopes in respiratory syncytial virus G protein central conserved region |
| WO2020033742A1 (en) | 2018-08-08 | 2020-02-13 | Trellis Bioscience, Llc | Improved rsv passive and active vaccines |
| US11201095B1 (en) | 2019-08-23 | 2021-12-14 | Xilinx, Inc. | Chip package having a cover with window |
| EP4125936A4 (en) * | 2020-03-23 | 2024-03-27 | Atossa Therapeutics, Inc. | HEPARIN AND N-ACETYLCYSTONE FOR TREATING A RESPIRATORY VIRUS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| CA2198279A1 (en) | 1994-08-25 | 1996-02-29 | Johannes Petrus Maria Langedijk | Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection |
| CA2240409C (en) † | 1996-01-24 | 2011-03-22 | Schering Corporation | Mammalian cx3c chemokine genes |
| AUPO026596A0 (en) | 1996-06-05 | 1996-06-27 | Biomolecular Research Institute Limited | Viral peptide |
| US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
| EP1010692A1 (en) | 1997-07-04 | 2000-06-21 | Chisso Corporation | Liquid-crystal compounds having large value of permittivity anisotropy, liquid-crystal composition containing the same, and liquid-crystal display element made using the liquid-crystal composition |
| ES2236946T3 (es) * | 1997-09-19 | 2005-07-16 | Wyeth Holdings Corporation | Peptidos derivados de la proteina de union (g) del virus respiratorio sincitial. |
| FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
-
2001
- 2001-10-18 CA CA2426312A patent/CA2426312C/en not_active Expired - Lifetime
- 2001-10-18 WO PCT/US2001/032459 patent/WO2002032942A2/en not_active Ceased
- 2001-10-18 AU AU2002224416A patent/AU2002224416A1/en not_active Abandoned
- 2001-10-18 DE DE60136381T patent/DE60136381D1/de not_active Expired - Lifetime
- 2001-10-18 AT AT01987765T patent/ATE412666T1/de not_active IP Right Cessation
- 2001-10-18 EP EP01987765.3A patent/EP1334119B2/en not_active Expired - Lifetime
- 2001-10-18 ES ES01987765T patent/ES2316487T5/es not_active Expired - Lifetime
- 2001-10-18 DK DK01987765.3T patent/DK1334119T4/da active
-
2003
- 2003-04-18 US US10/420,387 patent/US20040009177A1/en not_active Abandoned
-
2005
- 2005-05-26 US US11/139,372 patent/US8173131B2/en not_active Expired - Fee Related
-
2009
- 2009-03-12 AU AU2009200997A patent/AU2009200997B2/en not_active Expired
-
2012
- 2012-01-25 US US13/358,320 patent/US8778354B2/en not_active Expired - Fee Related
-
2014
- 2014-04-15 US US14/252,836 patent/US20140288267A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009200997B2 (en) | 2011-12-22 |
| CA2426312C (en) | 2014-01-14 |
| AU2009200997A1 (en) | 2009-04-02 |
| ES2316487T3 (es) | 2009-04-16 |
| WO2002032942A2 (en) | 2002-04-25 |
| CA2426312A1 (en) | 2002-04-25 |
| US20040009177A1 (en) | 2004-01-15 |
| ES2316487T5 (es) | 2019-05-13 |
| US20060018925A1 (en) | 2006-01-26 |
| ATE412666T1 (de) | 2008-11-15 |
| AU2002224416A1 (en) | 2002-04-29 |
| DK1334119T3 (da) | 2009-02-23 |
| US20140288267A1 (en) | 2014-09-25 |
| WO2002032942A3 (en) | 2002-12-12 |
| EP1334119B1 (en) | 2008-10-29 |
| US8778354B2 (en) | 2014-07-15 |
| DE60136381D1 (de) | 2008-12-11 |
| EP1334119A2 (en) | 2003-08-13 |
| US8173131B2 (en) | 2012-05-08 |
| US20120258111A1 (en) | 2012-10-11 |
| EP1334119B2 (en) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009200997B2 (en) | Compositions and methods for modulating RSV infection and immunity | |
| US6677127B1 (en) | Nucleic acid respiratory syncytial virus vaccines | |
| Olmsted et al. | Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. | |
| US5939068A (en) | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof | |
| Oshansky et al. | The host response and molecular pathogenesis associated with respiratory syncytial virus infection | |
| WO2022148374A1 (zh) | 抗冠状病毒的全人广谱中和抗体76e1及其应用 | |
| JP2016517440A (ja) | パリビズマブエピトープベースのウイルス様粒子 | |
| KR100550132B1 (ko) | 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드 | |
| CN114644708A (zh) | 呼吸道合胞病毒特异性结合分子 | |
| US11464850B2 (en) | Recombinant RSV antigens, nucleic acid molecules encoding the antigens, and vaccine compositions comprising the same | |
| EP0545951B1 (en) | Hrsv vaccine | |
| HK40061992B (zh) | Rsv f/g嵌合疫苗 | |
| WO2020033742A1 (en) | Improved rsv passive and active vaccines | |
| Mason | Antibodies specific to respiratory syncytial virus (RSV) G protein CX3C motif potentiate M2-specific CD8+ T cell response | |
| KR20180130632A (ko) | 호흡기 신시치아 바이러스에 특이적으로 결합하는 항체 및 이의 용도 |